Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS)

NCT05696392 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05696392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05696392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS)
Lead sponsor
Incyte Corporation
Phase
Phase 4
Overall status
Terminated
Start date
March 16, 2023
Completion date
January 22, 2025
Enrollment
47 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis